Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBECO SSI immunologic effects in resectable colon cancer
MOH_2020-10-07_009385Phase 2Not yet recruiting
- Sponsor
- Qu Biologics
- Start
- Mar 2020
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QBECO SSI in colon cancer, sponsored by Qu Biologics. Primary endpoint: Safety and tolerability. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
QBECO SSI
03
Conditions
colon cancer
Beyond the preview
Go deeper on MOH_2020-10-07_009385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-07_009385.